H Brevinge
Overview
Explore the profile of H Brevinge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindholm E, Brevinge H, Haglind E
Br J Surg
. 2008 Jun;
95(8):1029-36.
PMID: 18563785
Background: Early detection of colorectal cancer could reduce cancer-specific mortality. The aim of this trial was to evaluate the effect of faecal occult blood test (FOBT) screening on colorectal cancer...
2.
Borjesson L, Lundstam U, Oresland T, Brevinge H, Hulten L
Tech Coloproctol
. 2006 Sep;
10(3):237-41.
PMID: 16969610
Background: Conflicting views regarding the use of ileorectal anastomosis (IRA) in ulcerative colitis (UC) exist and this controversy prompted us to review our experience, especially against the background of the...
3.
Lindholm E, Brevinge H, Bergh C, Korner U, Lundholm K
Qual Life Res
. 2003 Sep;
12(5):575-82.
PMID: 13677502
Background: The purpose of this study was to evaluate to what extent self-reported health related quality of life (HRQL), assessed by the Swedish standard version of the Medical Outcome Study...
4.
Forslund A, Lonnroth C, Andersson M, Brevinge H, Lundholm K
J Clin Oncol
. 2001 Jun;
19(11):2829-36.
PMID: 11387354
Purpose: To compare p53 alterations in survivors and nonsurvivors after surgery for colorectal cancer. Patients And Methods: Twenty-nine potentially cured patients with colorectal carcinoma, without recurrent disease for more than...
5.
Kilhamn J, Brevinge H, Quiding-Jarbrink M, Svennerholm A, Jertborn M
Infect Immun
. 2001 Apr;
69(5):3466-71.
PMID: 11292777
The induction and dissemination of mucosal immune responses to recombinant cholera toxin B subunit (rCTB) administered into the ileal pouches of patients, who had been colectomized because of ulcerative colitis,...
6.
Yang Y, Forslund A, Remotti H, Lonnroth C, Andersson M, Brevinge H, et al.
Cancer
. 2001 Mar;
91(4):727-36.
PMID: 11241240
Background: The appearance of p53 mutations in colorectal carcinoma was determined, independent of differentiation and tumor stage of the primary tumors, in relation to the survival of patients who were...
7.
8.
Daneryd P, Svanberg E, Korner U, Lindholm E, Sandstrom R, Brevinge H, et al.
Cancer Res
. 1998 Dec;
58(23):5374-9.
PMID: 9850068
This study was aimed at evaluating whether anemia could be prevented in unselected weight-losing cancer patients on anti-inflammatory treatment by early and prophylactic treatment with recombinant human erythropoietin (rhEPO) and...
9.
Kilhamn J, Brevinge H, Svennerholm A, Jertborn M
Infect Immun
. 1998 Jul;
66(8):3995-9.
PMID: 9673295
The capacity of an oral inactivated B-subunit-whole-cell cholera vaccine to induce immune responses in patients colectomized due to ulcerative colitis was studied. Two doses of vaccine induced significant mucosal immunoglobulin...
10.
Brevinge H, Lindholm E, Buntzen S, KEWENTER J
Int J Colorectal Dis
. 1997 Jan;
12(5):291-5.
PMID: 9401844
Reduced mortality from colorectal cancer may be achieved by screening with faecal occult blood testing. Screening for neoplasia in the rectum and sigmoid colon with flexible sigmoidoscopy is suggested to...